Ovid Therapeutics Beats Q4 Earnings and Revenue Forecasts

Font: Financial Modeling Prep  • Mar 18, 2026

Ovid Therapeutics Inc. (NASDAQ:OVID) Surpasses Earnings and Revenue Estimates

• Ovid Therapeutics Inc. (NASDAQ:OVID) reported earnings per share of $0.06 for Q4 2025, beating the estimated loss of $0.10 per share.
• The company's revenue of $718,000 far exceeded estimates (which ranged from ~$13,000–$80,000 pre-release), showcasing significant growth.
• Ovid's financial position includes cash, cash equivalents, and marketable securities bolstered by a recent private placement; the company anticipates funding operations into the second half of 2028.

Ovid Therapeutics Inc. (NASDAQ:OVID) is a biopharmaceutical company focused on developing treatments for rare neurological disorders and brain conditions with significant unmet need. The company operates in the Zacks Medical - Biomedical and Genetics industry, where it competes with other firms in the development of innovative therapies. Ovid has made significant strides in its pipeline, particularly with its promising drug candidates OV329 (a next-generation GABA-aminotransferase inhibitor) and OV4071 (an oral KCC2 direct activator).

On March 18, 2026, OVID reported earnings per share of $0.06 for the fourth quarter of 2025, surpassing the Zacks Consensus Estimate of a $0.10 loss. This marks a substantial earnings surprise of approximately +158-161%, highlighting the company's improving financial health and operational momentum.

Ovid's revenue performance has also been impressive. The company reported revenue of $718,000 for Q4 2025, far exceeding consensus estimates. This represents strong growth compared to prior periods (e.g., significantly higher than year-ago figures in similar quarters).

The company's financial position is supported by cash, cash equivalents, and marketable securities, augmented by an October 2025 private placement (~$81 million upfront, with potential for more via warrants). This is expected to fund key studies for OV329 and OV4071 and support operations into the second half of 2028. The price-to-sales ratio (around 22x in recent data) suggests that investors remain optimistic about Ovid's future growth prospects in its differentiated neurological pipeline.